The following are some of the U.S. FDA’s actions taken, as of April 6, in its ongoing response effort to the COVID-19 pandemic: The FDA is leading an effort, working with government, industry and academic partners, to develop and implement a protocol that will provide convalescent plasma to patients in need across the country who may not have access to institutions with clinical trials in place. Convalescent plasma has the potential to lessen the severity or shorten the length of illness...